Myovant Sciences（纽约证券交易所代码：MYOV）和制药集团（纳斯达克股票代码：PHAR）的头对头调查

Myovant Sciences (NYSE:MYOV – Get Rating) and Pharming Group (NASDAQ:PHAR – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Myovant Sciences and Pharming Group, as provided by MarketBeat.com.

Get Myovant Sciences alerts:

Myovant Sciences presently has a consensus target price of $21.33, indicating a potential downside of 20.81%. Given Myovant Sciences' higher possible upside, research analysts plainly believe Myovant Sciences is more favorable than Pharming Group.

Volatility & Risk

Myovant Sciences has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.

Earnings & Valuation

This table compares Myovant Sciences and Pharming Group's gross revenue, earnings per share and valuation.

Pharming Group has lower revenue, but higher earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Myovant Sciences and Pharming Group's net margins, return on equity and return on assets.

Insider and Institutional Ownership

30.6% of Myovant Sciences shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 1.9% of Myovant Sciences shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pharming Group beats Myovant Sciences on 7 of the 12 factors compared between the two stocks.

About Myovant Sciences

(Get Rating)

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

About Pharming Group

(Get Rating)

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.